Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Debt Repayments (2021 - 2024)

Seres Therapeutics' Long-Term Debt Repayments history spans 5 years, with the latest figure at $127.9 million for Q3 2024.

  • For Q3 2024, Long-Term Debt Repayments changed N/A year-over-year to $127.9 million; the TTM value through Dec 2024 reached $127.9 million, up 141.97%, while the annual FY2024 figure was $127.9 million, 141.97% up from the prior year.
  • Long-Term Debt Repayments for Q3 2024 was $127.9 million at Seres Therapeutics, up from $52.9 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $127.9 million in Q3 2024 and bottomed at $948000.0 in Q4 2021.
  • The 4-year median for Long-Term Debt Repayments is $27.4 million (2022), against an average of $45.9 million.